American tennis player John Isner, who has been ranked as high as number 8 in men’s singles has just partnered with Defy to bring out a sports CBD-infused drink. Isner credits the drink to being a key factor in his muscle recovery process using cbd, helping him to get back on the court faster and stronger. He is the first tennis player to sign a CBD endorsement contract.
What does the collaboration mean?
Isner will wear Defy branded sports gear and he will drink the sports drink during matches ensuring it has high visibility. The company's co-founder is Terrell Davis, another sports star and a former player with the Denver Broncos.
Isner told media this week: “I play a sport where taking a single point off can be the difference between winning and losing a match and DEFY is a product specifically intended to put me in a position to perform on every single point,” explained Isner.
“It’s been great getting to know DEFY as a company and I look forward to working with them to help people achieve improved performance through CBD.”
DEFY’s formulation is based on hydration, electrolytes, taste and the quick replacement of vital nutrients. The formulation of 20mg/bottle provides the optimal amount of performance-spectrum CBD for individuals and athletes of all sizes. (It is important to note that bodily absorption is different for each person.)
Beau Wehrle, DEFY’s CEO said “DEFY is leading the way in CBD for professional sports. We know its benefits, impact on recovery and the direct relation to improved performance. It’s exciting to see pro tennis take the next important step for improving the lives of athletes everywhere.”
Professional athletes strive for every edge they can get and if they believe something can give them that, like CBD oil, they are all in. Tennis is one of the most physically taxing sports and is the next sporting arena to recognise the growing importance of CBD in athletics.
Alongside Terrell Davis and John Isner, DEFY will continue to educate and promote the acceptance of CBD in professional athletics.